Litcius/Paper detail

Manufacturing Bacteriophages (Part 1 of 2): Cell Line Development, Upstream, and Downstream Considerations

Tayfun Tanir, Marvin Orellana, Aster Escalante, Carolina Moraes de Souza, Michael Koeris

2021Pharmaceuticals18 citationsDOIOpen Access PDF

Abstract

Within this first part of the two-part series on phage manufacturing, we will give an overview of the process leading to bacteriophages as a drug substance, before covering the formulation into a drug product in the second part. The principal goal is to provide the reader with a comprehensive framework of the challenges and opportunities that present themselves when developing manufacturing processes for bacteriophage-based products. We will examine cell line development for manufacture, upstream and downstream processes, while also covering the additional opportunities that engineered bacteriophages present.

Topics & Concepts

Downstream (manufacturing)Upstream (networking)Upstream and downstream (DNA)BacteriophageDownstream processingProcess (computing)Process developmentDrug developmentComputer scienceNew product developmentManufacturing engineeringEngineeringBusinessDrugBiologyOperations managementTelecommunicationsOperating systemGeneEscherichia coliPharmacologyBiochemistryMarketingBacteriophages and microbial interactionsMonoclonal and Polyclonal Antibodies ResearchBacterial Genetics and Biotechnology
Manufacturing Bacteriophages (Part 1 of 2): Cell Line Development, Upstream, and Downstream Considerations | Litcius